grant
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy
Organization WASHINGTON UNIVERSITYLocation SAINT LOUIS, UNITED STATESPosted 23 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025AddressAdvanced CancerAdvanced Malignant NeoplasmAneuploid CellsAnimal ModelAnimal Models and Related StudiesAntioncogene Protein p53AnzataxApoptosisApoptosis PathwayAsotaxAutophagocytosisAutoregulationBiP geneBiP proteinBindingBristaxolCCND1 ProteinCDK4CDK4 geneCancer InductionCancer PatientCancer TreatmentCancer cell lineCancersCarcinomaCategoriesCell BodyCell Cycle ArrestCell Cycle ProgressionCell DeathCell Division Kinase 4Cell LineCell NucleusCell SurvivalCell ViabilityCellLineCellsCellular Tumor Antigen P53CentrosomeCessation of lifeChaperoneChromosomesClassificationClientClinical TrialsComplementComplement ProteinsComplexCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent KinasesCyclin-Dependent Protein KinasesDNA mutationDataDeathDefectDevelopmentDiseaseDisorderDoseDrug CombinationsDrug KineticsDrugsER stressEarly-Stage Clinical TrialsEndometrialEndometrial CancerEndometrial CarcinomaEndometrium CancerEndometrium CarcinomaEndoplasmic ReticulumEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelial CellsEpithelial cancerErgastoplasmFemale Reproductive CancerFutureG1 ArrestG1 BlockG1/S-Specific Cyclin D1GRP78GRP78 geneGene AlterationGene MutationGeneralized GrowthGenesGeneticGenetic ChangeGenetic InductionGenetic defectGenetic mutationGlucose-Regulated Protein, 78-kDGrantGrowthGrowth and DevelopmentGrowth and Development functionGynecologic CancerGynecological CancerHSPA5Heat shock proteinsHeat-Shock 70-kD Protein 5HeterograftHeterologous TransplantationHomeostasisIND FilingIND applicationIND packageIND submissionIncidenceInduction of ApoptosisIntermediary MetabolismInvestigational New Drug ApplicationKinasesMMAC1MMAC1 proteinMalignant CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant Female Reproductive System NeoplasmMalignant Gynecologic NeoplasmMalignant Gynecologic TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the Female Reproductive SystemMeasuresMediatingMedicationMetabolic ProcessesMetabolismMitochondriaMolecularMolecular ChaperonesMolecular FingerprintingMolecular InteractionMolecular ProfilingMutated in Multiple Advanced Cancers 1MutationNucleusOncogene ProductsOncogene ProteinsOncoprotein p53OncoproteinsOrganellesOrganoidsOutcomeOutcomes ResearchP53PHTS genePHTS proteinPRAD1 ProteinPSK-J3PTENPTEN genePTEN proteinPTEN1PaclitaxelPaclitaxel (Taxol)PatientsPharmaceutical PreparationsPharmacodynamicsPharmacokineticsPhasePhase 1 Clinical TrialsPhase 1b/2 Clinical TrialPhase 1b/II Clinical TrialPhase I Clinical TrialsPhase Ib/II Clinical TrialPhosphatase and Tensin HomologPhosphatase and Tensin Homolog Deleted on Chromosome 10Phosphoprotein P53Phosphoprotein pp53PhosphorylationPhosphotransferase GenePhosphotransferasesPhysiological HomeostasisPraxelPreparationProgrammed Cell DeathProgression-Free SurvivalsProliferatingProtein PhosphorylationProtein TP53ProteinsProto-Oncogene Proteins c-bcl-1RandomizedRecurrenceRecurrentRecurrent diseaseRefractoryRegulationRelapsed DiseaseResearch SpecimenRouteSHetA2ScheduleSerousSpecimenStrains Cell LinesStressSystematicsSystems BiologyTCGATP53TP53 geneTRP53TaxolTaxol ATaxol KonzentratTestingThe Cancer Genome AtlasTherapeuticTissue GrowthToxic effectToxicitiesTransphosphorylasesTreatment EfficacyTumor BurdenTumor LoadTumor Protein p53Tumor Protein p53 GeneUterusWomanXenograftXenograft procedureXenotransplantationadvanced diseaseadvanced illnessanti-cancer therapyautophagybcl-1 Proto-Oncogene Productsbcl-1 Proto-Oncogene Proteinsbcl1 Proto-Oncogene Proteinsbiomarker identificationc-bcl-1 Proteinscancer cellcancer survivalcancer therapycancer-directed therapycarcinogenesiscdk Proteinscomplementationcultured cell linecyclin Ddevelopmentaldrug detectiondrug testingdrug/agentendoplasmic reticulum stressepigeneticallyepithelial carcinomafirst in manfirst-in-humangene defectgenome mutationgynecologic malignancygynecological malignancyidentification of biomarkersidentification of new biomarkersimmunoglobulin heavy chain-binding proteinimprovedin vivoinhibitorintervention efficacymalignancymarker identificationmitochondrialmodel of animalmolecular profilemolecular signaturemortalinmortalitymutant allelemutated in multiple advanced cancers 1 proteinnecrocytosisneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyontogenyoverexpressoverexpressionp53 Antigenp53 Genesp53 Tumor Suppressorpatient prognosisphase 3 trialphase I protocolphase III trialphosphatase and tensin homologue on chromosome tenpre-clinical studypreclinical studypredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreparationspreventpreventingprotein complexprotein p53randomisationrandomizationrandomly assignedresponseside effectstandard of carestress proteinsynergismtherapeutic efficacytherapy efficacytumortumor growthwombxeno-transplantxeno-transplantation
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY
The incidence and mortality of endometrial cancer has increased over the past few decades, and is predicted to
continue rising. There is significant need for improved therapies with reduced toxicity for women with endometrial
cancers that are advanced, recurrent or refractory to standard of care. Endometrial cancer is a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click